Guanylate Cyclase Stimulators

Soluble Guanylate Cyclase Stimulator

Hypertension, Pulmonary

<section class="Section" data-sectioncode="34089-3"><a name="ID_740cdc1e-fcff-413d-b928-5ef125622626"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Adempas (riociguat) is a soluble guanylate cyclase stimulator tablet for oral administration. Riociguat is methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate with the following structural formula:</p><div class="Figure"><a name="id2030361332"></a><img alt="Chemical Structure" src="e9e1a668-1b31-4094-88b7-2004f94af53d-01.jpg"/></div><p>C<span class="Sub">20</span>H<span class="Sub">19</span>FN<span class="Sub">8</span>O<span class="Sub">2</span></p><p>Riociguat is a white to yellowish, crystalline, non-hygroscopic substance with a molecular weight of 422.42 g/mol. In solid form it is stable to temperature, light, and humidity. </p><p>The solubility at 25°C in water: 4 mg/L, in ethanol: 800 mg/L, in 0.1 HCl (pH 1): 250 mg/L and in buffer (phosphate) pH 7: 3 mg/L. In the pH range of 2 to 4 the solubility showed strong pH-dependency. Solubility increases at lower pH values.</p><p>Each round film-coated tablet contains 0.5 mg (1.0, 1.5, 2.0, 2.5 mg) riociguat. The inactive ingredients are cellulose microcrystalline, crospovidone, hypromellose 5cP, lactose monohydrate, magnesium stearate, sodium laurylsulfate, hydroxypropylcellulose, hypromellose 3cP, propylene glycol, and titanium dioxide. Adempas 1, 1.5, 2 and 2.5 mg tablets contain, in addition, ferric oxide yellow. Adempas 2 and 2.5 mg tablets contain, in addition, ferric oxide red.</p></section>

Adempas

riociguat

riociguat 0.5 MG Oral Tablet

riociguat 1.5 MG Oral Tablet

riociguat 1 MG Oral Tablet

riociguat 2.5 MG Oral Tablet

riociguat 2 MG Oral Tablet

riociguat 0.5 MG Oral Tablet [Adempas]

riociguat 1 MG Oral Tablet [Adempas]

riociguat 1.5 MG Oral Tablet [Adempas]

riociguat 2 MG Oral Tablet [Adempas]

riociguat 2.5 MG Oral Tablet [Adempas]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Formulary Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Adempas Prescription & Aim Support Program Enrollment Form

Adempas Prescription & Aim Support Program Enrollment Form - Spanish

Adempas Prescription & Aim Support Program Enrollment Form - VA Patients

Enroll in Patient Savings Program 

Other HCP Resources: Diagnostic Resources

Other HCP Resources: Video Library

About Adempas

Taking Adempas

Side Effects

Caregiver Tips

FAQS: PAH & CTEPH

Aim Patient Support Program 

Patient Resources

Doctor Discussion Guide: Newly Diagnosed PAH Patients

Doctor Discussion Guide: Patients with PAH Receiving Treatment

Doctor Discussion Guide for Patients with CTEPH

Instructions For Use: Pulmonary Arterial Hypertension (PAH)

Instructions For Use: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)